377 related articles for article (PubMed ID: 20337579)
1. Old versus new anticoagulants: focus on pharmacology.
Benmira S; Banda ZK; Bhattacharya V
Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):120-37. PubMed ID: 20337579
[TBL] [Abstract][Full Text] [Related]
2. The promise of novel direct oral anticoagulants.
Hoffman R; Brenner B
Best Pract Res Clin Haematol; 2012 Sep; 25(3):351-60. PubMed ID: 22959551
[TBL] [Abstract][Full Text] [Related]
3. Beyond unfractionated heparin and warfarin: current and future advances.
Hirsh J; O'Donnell M; Eikelboom JW
Circulation; 2007 Jul; 116(5):552-60. PubMed ID: 17664384
[No Abstract] [Full Text] [Related]
4. [From heparin to apixaban: anticoagulants cut both ways?].
Hartung K; Meyer F; Bock F; Isermann B
Zentralbl Chir; 2014 Feb; 139(1):89-97. PubMed ID: 23460104
[TBL] [Abstract][Full Text] [Related]
5. New oral anticoagulants: should they replace heparins and warfarin?
Tsiara S; Pappas K; Boutsis D; Laffan M
Hellenic J Cardiol; 2011; 52(1):52-67. PubMed ID: 21292607
[No Abstract] [Full Text] [Related]
6. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
Ufer M
Thromb Haemost; 2010 Mar; 103(3):572-85. PubMed ID: 20135071
[TBL] [Abstract][Full Text] [Related]
7. Disadvantages of VKA and requirements for novel anticoagulants.
Shameem R; Ansell J
Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
[TBL] [Abstract][Full Text] [Related]
8. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
9. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Quinlan DJ; Eriksson BI
Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
[TBL] [Abstract][Full Text] [Related]
10. New anticoagulants for the prevention of thromboembolism.
Lepic K; Crowther M
Curr Pharm Des; 2010; 16(31):3472-4. PubMed ID: 20858184
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
Ordovás Baines JP; Climent Grana E; Jover Botella A; Valero García I
Farm Hosp; 2009; 33(3):125-33. PubMed ID: 19712596
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulation: a GP primer on the new oral anticoagulants.
Brieger D
Aust Fam Physician; 2014 May; 43(5):254-9. PubMed ID: 24791763
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Hellwig T; Gulseth M
Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
[TBL] [Abstract][Full Text] [Related]
15. New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Baker WL; Chamberlin KW
Clin Pharmacol Ther; 2014 Jul; 96(1):17-9. PubMed ID: 24942397
[TBL] [Abstract][Full Text] [Related]
16. Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.
Mangiafico RA; Mangiafico M
Curr Med Chem; 2012; 19(27):4688-98. PubMed ID: 22830344
[TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Sattari M; Lowenthal DT
Am J Ther; 2011 Jul; 18(4):332-8. PubMed ID: 20535013
[TBL] [Abstract][Full Text] [Related]
18. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
19. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
20. [New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics].
Marco P; Tarín F; Lucas J
Med Clin (Barc); 2008 Nov; 131 Suppl 2():66-9. PubMed ID: 19087854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
